NASDAQ · Biotechnology

APVO (APVO) Stock

$4.21 -4.10% NASDAQ: APVO Healthcare

Valuation

MetricValue
Price$4.21
Market Cap$9.21M
P/E Ratio-0.06
P/B Ratio0.50
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$70.65
52-Week Low$3.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-517.92%
ROA-1.18%
ROCE-152.94%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.38
Current Ratio3.83

Annual Financials (USD)

Metric20212022202320242025
Revenue$12.0M$3.0M$0$0$0
Operating Profit$-21.0M$-29.0M$-29.0M$-25.0M$-26.0M
Net Profit$-28.0M$8.0M$-17.0M$-24.0M$-26.0M
EPS$-3557646.00$921915.00$-834044.00$-31458.00$-87.27
Op Margin-174.1%-919.8%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$57.0M$34.0M$25.0M$16.0M$27.0M
Total Liabilities$55.0M$16.0M$13.0M$11.0M$10.0M
Cash$45.0M$23.0M$17.0M$9.0M$22.0M
Borrowings$17.0M$10.0M$5.0M$5.0M$5.0M

Latest News

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors ACCESS Newswire · Jun 30, 2026 APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement Zacks Small Cap Research · Jun 16, 2026 Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer ACCESS Newswire · May 28, 2026 Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing ACCESS Newswire · May 27, 2026 All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy Zacks · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-22.0M$-21.0M$-12.0M$-24.0M$-26.0M
Investing Cash Flow$-1.0M$0$0$0$0
Financing Cash Flow$26.0M$3.0M$3.0M$6.0M$0
Net Cash Flow$4.0M$-24.0M$-6.0M$-8.0M$13.0M
Free Cash Flow$-22.0M$-21.0M$-12.0M$-24.0M$-26.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA0.16
FCF Yield-255.72%
Quick Ratio3.36
Interest Coverage—
Return 1Y-91.31%
Return 3Y-100.00%
Return 5Y-100.00%

Ownership

Insiders Held7.97%
Institutions Held4.45%
Institutions Float Held4.84%
Institutional HolderSharesReport Date
GSA Capital Partners LLP19,6382026-03-31
Geode Capital Management, LLC13,3372026-03-31
Vanguard Capital Management LLC12,7132026-03-31
Vanguard Fiduciary Trust Co4,1422026-03-31
UBS Group AG3,4452026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About APVO

APVO is led by CEO Jeffrey G. Lamothe, employs 37 people, headquartered in US, publicly traded since 2016.

APVO stock trades at $4.21 with a market capitalization of $9.21M. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 0.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.80 and $70.65, and currently trades 94.0% below its 52-week high.

On profitability, APVO generates a return on equity (ROE) of -517.92%, return on capital employed of -152.94%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides